Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 24:13:937490.
doi: 10.3389/fphar.2022.937490. eCollection 2022.

The Inflammatory Factor SNP May Serve as a Promising Biomarker for Acitretin to Alleviate Secondary Failure of Response to TNF-a Monoclonal Antibodies in Psoriasis

Lanmei Lin  1 , Yilun Wang  1 , Xiaonian Lu  1 , Tianxiao Wang  2 , Qunyi Li  2 , Runnan Wang  1 , Jinfeng Wu  1 , Jinhua Xu  1 , Juan Du  1
Affiliations

The Inflammatory Factor SNP May Serve as a Promising Biomarker for Acitretin to Alleviate Secondary Failure of Response to TNF-a Monoclonal Antibodies in Psoriasis

Lanmei Lin et al. Front Pharmacol. .

Abstract

Psoriasis is a common immune-mediated inflammatory skin disease. Although biological agents have achieved good clinical efficacy in the treatment of moderate-to-severe psoriasis, the phenomenon of secondary non-response (SNR) has been gradually recognized. SNR refers to the gradual decline of efficacy after the patient achieves clinical remission with biological agents such as TNF-α biologics. Acitretin, as an immunomodulatory systemic drug for psoriasis, can improve the SNR to biological agents with good tolerance, but there are still individual differences in efficacy. Single-nucleotide polymorphisms (SNPs) of many related inflammatory cytokines have been shown to be important factors of individual differences in drug response in psoriasis, but there have been few reports on the use of pharmacogenomics to alleviate the SNR to biological agents. This study recruited 43 patients with psoriasis and 24 normal controls to investigate whether SNPs of inflammatory cytokines could be used as biomarkers for acitretin to alleviate SNR to TNF-α biologics in psoriasis, including rs1800795 (IL-6), rs6887695 (IL-12b), rs3212227 (IL-12b), rs10484879 (IL-17a), rs4819554 (IL-17ra), rs763780 (IL-17F), rs11209032 (IL23R), rs11209026 (IL23R), and rs2201841 (IL23R). The study also analyzed the correlation between the abovementioned SNPs and the efficacy of acitretin-only patients so as to understand whether the improvement is attributable to the intervention of acitretin on SNR or a simple response of acitretin. We found that in patients with homozygous AA (χ2 = 6.577, p = 0.02) at the SNP rs112009032 (IL-23R), acitretin could improve the SNR to TNFα monoclonal antibody. Patients with the genotype of TG (χ2 = 6.124, p = 0.035) at rs3212227 (IL-12B) were more sensitive to using acitretin in the treatment of psoriasis. Rs3212227 (χ2 = 7.664, p = 0.022) was also associated with the susceptibility to psoriasis. The study might provide a clinical decision reference for personalized treatment of secondary loss of response to psoriasis biologics.

Keywords: acitretin; biologics; psoriasis; secondary non-response; single-nucleotide polymorphism (SNP).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The flowchart of clinical trials and analysis in this study.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Amatore F., Villani A.-P., Tauber M., Viguier M., Guillot B., and Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie) (2019). French Guidelines on the Use of Systemic Treatments for Moderate-To-Severe Psoriasis in Adults. J. Eur. Acad. Dermatol Venereol. 33, 464–483. 10.1111/jdv.15340 - DOI - PMC - PubMed
    1. Armstrong A. W., Bagel J., Van Voorhees A. S., Robertson A. D., Yamauchi P. S. (2015). Combining Biologic Therapies with Other Systemic Treatments in Psoriasis: Evidence-Based, Best-Practice Recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol 151, 432–438. 10.1001/jamadermatol.2014.3456 - DOI - PubMed
    1. Ben-Horin S., Waterman M., Kopylov U., Yavzori M., Picard O., Fudim E., et al. (2013). Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients with Inflammatory Bowel Disease. Clin. Gastroenterol. Hepatol. 11, 444–447. 10.1016/j.cgh.2012.10.020 - DOI - PubMed
    1. Białecka M., Ostasz R., Kurzawski M., Klimowicz A., Fabiańczyk H., Bojko P., et al. (2015). IL6 -174G>C Polymorphism Is Associated with an Increased Risk of Psoriasis but Not Response to Treatment. Exp. Dermatol 24, 146–147. 10.1111/exd.12577 - DOI - PubMed
    1. Billi A. C., Gudjonsson J. E., Voorhees J. J. (2019). Psoriasis: Past, Present, and Future. J. Invest. Dermatol 139, e133–e142. 10.1016/j.jid.2019.08.437 - DOI - PMC - PubMed